Version July 2025
| Drug | US brand (trade) name | Usual oral daily dose range (mg)*¶ |
| ACE inhibitors | ||
| Benazepril | Lotensin | 10 to 40 (maximum 80 mg) |
| Captopril | Capoten (only available in US as generic preparation) | 25 to 150 in two or three divided doses |
| CilazaprilΔ | Inhibace (Canadian trade name) | 2.5 to 5 |
| Enalapril | Vasotec | 10 to 40 |
| Fosinopril | Monopril (only available in US as generic preparation) | 10 to 40 (maximum 80 mg) |
| Lisinopril | Prinivil, Zestril | 10 to 40 |
| Moexipril | Univasc | 7.5 to 30 |
| Perindopril | Aceon | 4 to 8 (maximum 16 mg) |
| Quinapril | Accupril | 10 to 40 |
| Ramipril | Altace | 2.5 to 10 (maximum 20 mg) |
| Trandolapril | Mavik | 1 to 4 (maximum 8 mg) |
| Angiotensin II receptor antagonists | ||
| Azilsartan | Edarbi | 80 |
| Candesartan | Atacand | 8 to 32 |
| Eprosartan | Teveten | 600 to 800 |
| Irbesartan | Avapro | 150 to 300 |
| Losartan | Cozaar | 50 to 100 |
| Olmesartan | Benicar | 20 to 40 |
| Telmisartan | Micardis | 40 to 80 |
| Valsartan | Diovan | 80 to 320 |
* Doses as low as one-half or one-quarter of the lower dose shown may be used initially in high-risk patients such as those with heart failure, significant renal insufficiency, hyponatremia, intravascular volume depletion, or those receiving concurrent treatment with a diuretic.
¶ Giving one-half the dose twice a day is an alternative that produces a lesser peak effect but a more sustained response; however, patient compliance may be reduced. In patients who do not respond to a moderate dose, we suggest sequential monotherapy for optimizing initial drug selection in most patients rather than use of maximum doses shown in this table. Refer to discussion in UpToDate topic review of choice of drug therapy in primary hypertension for detail.
Δ Not available in US.